Nilotinib and Parkinson's Disease

1. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis Nilotinib and Parkinson's Disease Nilotinib For Parkinson's, Nilotinib Parkinson www.genuinedrugs123.com

2. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis Are you suffering from Parkinson's Disease ?? www.genuinedrugs123.com

3. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis ANY specialist doctor have suggested nilotinibfor parkinson's ?? www.genuinedrugs123.com

4. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis WANT TO KNOW MORE, contact with a genuine online pharmacy www.genuinedrugs123.com

5. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis ARE YOU CONFUSED IN FINDING RIGHT SOURCE ?? www.genuinedrugs123.com

6. Latest update - Research on NILOTINIB drug for treatment of ALZHEIMER’S / PARKINSON’S Disease A New Use for Nilotinib... Oncology Times: January 10th, 2016 - Volume 38 - Issue 1 - p 32 doi: 10.1097/01.COT.0000479762.08172.57 News Tyrosine kinase inhibitors (TKIs) have changed the treatment paradigm for patients with chronic myelogenous leukemia (CML), and new research suggests one of the agents could potentially do the same for patients with Parkinson's disease. Researchers found that nilotinib (marketed as Tasigna by Novartis)—approved by the U.S. Food and Drug Administration for the treatment of patients with CML (OT 7/10/10 issue)—improved cognition, motor skills, and non-motor function for patients with Parkinson's disease and Lewy body dementia. Complete data from the Phase I clinical trial were presented at the Annual Meeting of the Society for Neuroscience in October (Program 12,Poster1

7. “When used in higher doses for CML, nilotinib forces cancer cells into autophagy—a biological process that leads to the death of tumor cells,” study coauthor CharbelMoussa, MD, PhD, Director of Georgetown's Laboratory of Dementia and Parkinsonism, explained in a news release. “The dose used in CML treatment is significantly higher than what we used in our Parkinson's study. “It appears that in smaller doses once a day, nilotinib turns on autophagy for about four to eight hours—long enough to clean out the cells without causing cell death. Then proteins that build up again will be cleared when the drug is given again the next day.” The observed efficacy in cognition, motor skills, and non-motor function improvement (such as constipation) for many patients was the most dramatic result, the researchers reported, according to the news release. One individual confined to a wheelchair was able to walk again; three others who could not talk were able to hold conversations.

8. Study Details The study included 11 patients with advanced Parkinson's disease, Parkinson's disease with dementia, or Lewy body dementia, who received 150 to 300 mg nilotinib daily for six months. All patients benefited from the drug, and 10 had clinically meaningful improvements. Patients also showed positive changes in relevant cerebrospinal fluid biomarkers of Parkinson's, including alpha-synuclein (α-synuclein), amyloid beta-40/42 (Abeta-40/42), and dopamine, with statistically significant changes in total Tau and p-Tau. Prior studies show that α-synuclein and Abeta 40/42 in cerebrospinal fluid are decreased as Parkinson's worsens, while Tau and p-Tau are increased in cerebrospinal fluid with the onset of dementia. “The changes in Tau, p-Tau, α-synuclein and Abeta-40 and 42 in spinal fluid suggest the clearance of toxic proteins in the brain,” another study coauthor Fernando Pagan, MD, a Georgetown University Medical Center Associate Professor of Neurology and Director of the Movement Disorders Program at MedStar Georgetown University Hospital, said, also in a news release.

9. “To my knowledge, this study represents the first time a therapy appears to reverse—to a greater or lesser degree depending on stage of disease—cognitive and motor decline in patients with these neurodegenerative disorders,” Pagan added. “But it is critical to conduct larger and more comprehensive studies before determining the drug's true impact.” No serious side effects were reported and the drug was well tolerated by the patients on the trial. Why Try a Cancer Drug? Moussa's preclinical research led him to think about using cancer drugs to treat neurological disorders. He was looking for an FDA-approved drug that could penetrate the blood-brain barrier and turn on the “garbage disposal machinery” inside neurons to clear toxic intracellular proteins and prevent their accumulation within, or secretion outside of, brain cells, he noted. Moussa is an inventor on a Georgetown University patent application for use of nilotinib and other tyrosine kinase inhibitors for the treatment of neurodegenerative disease.

10. At the end of this study patients were given the option to continue taking nilotinib (provided by Novartis) as part of an expanded access study. Moussa and other Georgetown researchers are now planning larger clinical trials with nilotinib for patients with Parkinson's and other similar diseases including Alzheimer's disease, likely to begin in 2016. Source- https://journals.lww.com/oncology-times/fulltext/2016/01100/A_New_Use_for_Nilotinib___.12.aspx Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

11. NEW CLINICAL TRIAL WILL TEST CANCER DRUG AS ALZHEIMER’S TREATMENT - September 29, 2016 The Alzheimer’s Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna® for use as a cancer therapy) in patients with Alzheimer’s disease. Nilotinib is an FDA-approved drug for the treatment of adult chronic myeloid leukemia. In preclinical studies conducted by Georgetown researchers, nilotinib reduced cognitive impairment by targeting two of the underlying causes of Alzheimer’s—neuroinflammation and misfolded proteins. Nilotinib triggers a process (called autophagy) that removes the toxic proteins tau and beta-amyloid from the brain before they accumulate into plaques and tangles.

12. Dr. Turner, co-medical director of Georgetown University Medical Center’s Translational Neurotherapeutics Program (TNP) and director of the Georgetown Memory Disorders Program, says, “By stimulating the brain’s normal autophagic process, which clears out these misfolded proteins in cells, we hope to prevent or slow the progression of Alzheimer’s. In fact, nilotinib may be a first—a broad-spectrum anti-neurodegenerative drug that targets all misfolded protein aggregates that accumulate in the brain of Alzheimer’s patients. By targeting both amyloid and tau, this study may point the way to a new strategy in Alzheimer’s disease treatment.” The preclinical research was conducted by CharbelMoussa, MD, PhD, scientific and clinical research director for Georgetown’s TNP, who explains, “Nilotinib seems to activate the cell’s garbage disposal machine, reduce plaques and tangles and reverse cognitive decline in animal models of Alzheimer’s disease. We hope that this trial will clarify the effects of nilotinib in Alzheimer’s patients.” Moussa will be a co-investigator on the Alzheimer’s trial.

13. The trial is expected to start this year and will include 42 patients, with half randomized to receive an escalating dose of nilotinib, while the other half receives a placebo. The primary objectives of the study will be to test the drug’s safety and tolerability and to measure whether nilotinib reduces inflammation and the presence of beta-amyloid and tau in spinal fluid. Dr. Turner and his colleagues in the Georgetown Memory Disorders Program will also perform cognitive and functional abilities tests. Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, says: “The ADDF is proud to support a clinical trial that holds such promise for Alzheimer’s patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer’s.” The ADDF’s initiative “Learning from Cancer to Advance Treatments for Neurodegenerative Diseases” launched in 2015 with a conference held in partnership with the New York Academy of Sciences. Its goal is both to develop new therapies and test existing cancer therapies for their potential in treating Alzheimer’s disease. In addition to the nilotinib trial at Georgetown, this initiative includes funding for drug development projects at Oryzon Genomics, Rodin Therapeutics, and Yuma Therapeutics. Source- https://www.alzdiscovery.org/news-room/announcements/new-clinical-trial-will-test-cancer-drug-as-alzheimers-treatment

14. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis contact us www.genuinedrugs123.com

15. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis We will help you to get it at an affordable price www.genuinedrugs123.com

16. Author- Christopher Buegles found Nilotinib drug (Tasigna) selling at most competitive prices in certain pharmacies globally. Universaldrugstore.com 112 capsules for $ 3975 Pharmstore.com 112 capsules for $ 3984.99 Buynilotinibonline.com 112 capsules for $ 4074 Drugmartdirect.com 112 capsules for $ 3984.24 Cancercurepharmacy.com 112 capsules for $ 3607 Globalcarerx.com 112 capsules for $ 3975 GenuineDrugs123.com 112 capsules for $ 3656 Planetdrugsdirect.com 112 capsules for $ 5836.99 Northdrugstore.com 112 capsules for $ 3975 Pricing as on 21.11.18 www.genuinedrugs123.com

17. Drugs available for Cancer | HIV/AIDS | Hepatitis | Diabetes | COPD | CKD | Cholesterol | Osteoporosis https://bit.ly/2KkSYCE www.genuinedrugs123.com